Skip to content

The Study of Jian Pi Yi Shen Hua Tan Granules in Cognitive Impairment After Acute Cerebral Infarction

A Study to Evaluate the Safety and Efficacy of Jian Pi Yi Shen Hua Tan Granules in Patients With Cognitive Impairment After Acute Cerebral Infarction

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02641886
Enrollment
300
Registered
2015-12-30
Start date
2016-03-09
Completion date
2019-04-18
Last updated
2019-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment

Keywords

traditional Chinese medicine granules, Cognitive Impairment, Acute cerebral infraction, prevention

Brief summary

The purpose of this study is to determine whether the chinese medicine Jian Pi Yi Shen Hua Tan granules is effective in the treatment of cognitive impairment after acute cerebral infarction .

Detailed description

The present study is designed to observe the symptoms,syndrome characteristics and neuropsychological changes of patients with cognitive dysfunction after Acute Cerebral Infarction, as well as study the patterns of syndrome evolution and neuropsychological characteristics, in order to provide evidences for the early-stage identification, diagnosis, intervention and treatment based on syndrome differentiation. To assess the effectiveness of applying early-stage prevention on patients with cognitive impairment after Acute Cerebral Infarction through the use of traditional Chinese medicine--Jian Pi Yi Shen Hua Tan granules, explore the pathogenesis and therapeutic efficacy mechanism, evaluate the effectiveness of early-stage prevention and provide alternative solutions for preventing or delaying dementia.

Interventions

DRUGJian Pi Yi Shen Hua Tan Granules

Jianpi Yishen Huatan Granules contain Herba cistanche,Fructus Alpinia Oxyphyllae,Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one

Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one

Sponsors

Changchun University of Chinese Medicine
CollaboratorOTHER
Chongqing Traditional Chinese Medicine Hospital
CollaboratorOTHER
Jiangmen Wuyi Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Shunyi Hospital of Traditional Chinese Medicine
CollaboratorUNKNOWN
Dongfang Hospital Beijing University of Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients conform to the diagnostic criteria of acute ischemic stroke Online Certificate Status Protocol classification of cerebral infarction : Partial Anterior Circulation Infarct, Posterior Circulation Infarct or Lacunar Infarction - Stroke onset within 14 days * Neuropsychological assessments: Montreal Cognitive Assessment Scale scores less than 26 points or scores less than 27 points,MMSE scores range from 19 points to 26 points * Age from forty to eighty, gender not limited * Informed and signed the informed consent

Exclusion criteria

* Transient Ischemic Attack * Online Certificate Status Protocol classification of cerebral infarction is a total anterior circulation infarction * Stroke patients with the causes of cerebral hemorrhage, subarachnoid hemorrhage, brain tumors, brain injury, or blood diseases and so on. * Stroke with an onset of more than 14 days * Cerebral embolism caused by atrial fibrillation resulted from rheumatic heart disease, coronary heart disease and other heart diseases. * Patients who cannot cooperate with the check due to serious visual, hearing dysfunction, apraxia, aphasia. * Patients with other neurological diseases which can affect cognitive function (for example: severe Parkinson's disease, normal pressure hydrocephalus, brain tumors, encephalitis) * Patients with communication difficulties, or psychiatric disease * Depression (Hamilton Depression Scale scores more than or equal to 17 points) Diagnosed with alcohol or drug dependence within the past six months * With other diseases which can cause cognitive dysfunction, Such as thyroid dysfunction, severe anemia, syphilis, Human Immunodeficiency Virus and so on * With a previous history of stroke and serious sequelae, and cannot cope with neuropsychological examination * With severe primary diseases, and cannot comply with the above scheme

Design outcomes

Primary

MeasureTime frameDescription
Verbal memory test(HVLT)90 daysUsing Verbal memory test(HVLT) to examine verbal memory
Montreal Cognitive Assessment scale90 daysUsing Montreal Cognitive Assessment scale to examine the patients' cognitive function
Stroop test90 daysUsing Stroop test to examine executive function and attention
Numerical sequence test(DS-S)90 daysUsing Numerical sequence test(DS-S) to examine memeory
Digital color connection test (CCT)90 daysUsing Numerical sequence test(DS-S) to examine executive function and attention
mini-mental state examination90 daysUsing mini-mental state examination to examine the patients' cognitive function

Secondary

MeasureTime frameDescription
modified Rankin scale90 daysUsing modified Rankin scale to examine the recovery of neurologic function
Activity of Daily Living Scale90 daysUsing Activity of Daily Living Scale to examine daily living ability
scores of Chinese medicine symptoms90 daysUsing the scores of Chinese medicine symptoms to examine the Chinese medicine syndrom
national institute of health stroke scale90 daysUsing national institute of health stroke scale to examine the neurologic function impairment

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026